大胃GIST微创手术真的安全吗?短期与长期结局对比分析
基于美国国家癌症数据库2017年数据,纳入3765例5-10 cm或T3期胃GIST患者,比较微创与开腹手术的围术期及长期结局。微创组住院时间更短,R1切缘无显著差异,再入院、30天及90天死亡率更低,总生存无显著差异。
要点
- 5-10 cm胃GIST微创手术住院时间短于开腹(4.77 vs 7.04天,p<0.001)。
- R1切缘率微创2.9% vs 开腹3.1%,无显著差异(p=0.143)。
- 微创组再入院、30天及90天死亡率均低于开腹组,总生存无显著差异。
核心结论
- 5-10 cm胃GIST微创手术可能不仅改善术后并发症,也具有肿瘤学安全性。
- 两种术式长期生存相似,国家指南可能需要纳入这一新信息。
研究设计与样本
- 查询美国国家癌症数据库(NCDB)2017年数据,纳入5-10 cm或T3期胃GIST患者3765例。
- 采用二元逻辑回归、线性回归模型和Kaplan-Meier生存分析。
主要发现
- 平均肿瘤大小67.3 mm,微创占26.3%,开腹占73.8%。
- 中位住院时间微创4.77天 vs 开腹7.04天(p<0.001)。
- R1切缘微创2.9% vs 开腹3.1%(p=0.143),无显著差异。
- 非计划再入院微创2.9% vs 开腹4.1%(OR 0.474,p=0.025),30天死亡率微创0.5% vs 开腹1.2%(OR 0.325,p=0.031),90天死亡率微创0.9% vs 开腹2.1%(OR 0.478,p=0.036)。
- Cox回归模型显示总生存无差异(p=0.137,HR 0.808)。
临床怎么用
- 对于5-10 cm或T3期胃GIST,微创手术可考虑作为改善术后恢复的选择。
- 微创手术未显示R1切缘或长期生存劣于开腹手术。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: While minimally invasive surgery (MIS) is frequently utilized to remove small gastric gastrointestinal stromal tumors (GIST), MIS surgery for tumors ≥ 5 cm is currently not endorsed by national guidelines as standard of care due to concerns of safety and inferior oncologic outcomes. Hence this study investigates the perioperative and long-term outcomes of MIS for T3 gastric GIST measuring 5-10 cm. METHODS: The National Cancer Database (NCDB) 2017 was queried for gastric GIST measuring 5-10 cm or T3 category. Inclusion criteria were known: stage, size, comorbidities, grade, lymphovascular invasion, type of surgery, approach, conversion info, margin status, mitotic rate, neoadjuvant and adjuvant treatment, hospital stay, readmission, 30- and 90-day mortality, complete follow-up, type of institution, and hospital gastric surgery case volume. Binary logistic regression, linear regression models, and Kaplan-Meier survival analysis were used. RESULTS: In 3765 patients, mean tumor size was 67.3 mm; 26.3% MIS; and 73.8% open. Median hospital stay was shorter for MIS (4.77 vs 7.04 days, p < 0.001). There was no significant difference in incidence of R1 margins [2.9% MIS vs. 3.1% open (p = 0.143)], unplanned readmission [2.9% MIS and 4.1% open (OR 0.474 p = 0.025)], 30-day mortality [0.5% MIS vs 1.2% open (OR 0.325, p = 0.031)], and 90-day mortality [0.9% MIS vs 2.1% open (OR 0.478 p = 0.036)]. Cox regression models for OS showed no difference in survival (p = 0.137, HR 0.808). CONCLUSION: This analysis provides substantial evidence that MIS for gastric GIST ≥ 5-10 cm may not only offer improved postoperative morbidity but also oncologic safety. Moreover, as both approaches lead to similar long-term survival, national guidelines may need to incorporate this new information.
引用
- Crocker AB, Vega EA, Kutlu OC, et al. Is minimally invasive surgery for large gastric GIST actually safe? A comparative analysis of short- and long-term outcomes. Surg Endosc. 2022. PMID: 35312847. doi:10.1007/s00464-022-09066-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。